Regencell Bioscience continued to rise 13% in premarket trading, the stock has gained nearly 160% in the past three trading days.

Regencell’s goal is to treat neurological disorders like ADHD and autism spectrum disorder through herb-based medicines. Its traditional Chinese formula, which forms the basis of product candidates, “contains only natural ingredients without any synthetic components,” according to its website.

Precious metals shares slid in premarket trading. Sibanye down over 4%; First Majestic Silver down 3%; Coeur Mining, Pan American Silver down over 2%.

Rare earth stocks fell in premarket trading. Critical Metals down about 6%; American Resources down over 5%; MP Materials, USA Rare Earth down about 3%.